They engineered CARs modified with IL-8 receptors, CXCR1, and CXCR2, demonstrating that these modified CARs could be guided to migrate into tumors, inducing an enhanced anti-tumor response in solid tumors [62]. This evidence concerns the gene CXCR2 and neoplasm.